Navigation Links
Omeros Reports Phase 3 OMS302 Clinical Data Presented at the Annual American Academy of Ophthalmology Meeting
Date:11/19/2013

platform, which is making available an unprecedented number of new GPCR drug targets and corresponding compounds to the pharmaceutical industry for drug development.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the "safe harbor" created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with Omeros' unproven preclinical and clinical development activities, regulatory oversight, product commercialization, intellectual property claims and the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2013. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.

Image with caption: "Data from Omeros' Phase 3 Clinical Program (Studies ILR003 and ILR004): Effect of OMS302 vs Control on Miosis." Image available at: http://photos.prnewswire.com/prnh/20131119/MM19781<
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros to Present at Deutsche Bank Securities Health Care Conference
2. Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio
3. Omeros to Present at Jefferies 2012 Global Healthcare Conference
4. Omeros Announces Proposed Public Offering of Common Stock
5. Omeros Prices $30 Million Public Offering of Common Stock
6. Omeros Announces Closing of $34.5 Million Public Offering of Common Stock
7. Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway
8. Omeros Announces Discovery in MASP-2 Program
9. Omeros Corporation Reports Second Quarter 2012 Financial Results
10. Omeros Announces Completion of Enrollment in OMS103HP Phase 3 Clinical Trial
11. Omeros to Present at Two Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 27, 2015 OpportunityAnalyzer: Sepsis - Opportunity Analysis ... suffer from a series of diverse complications arising from ... blood or tissues, which cause a rapidly progressing hyperactive ... rates near 50% depending on disease severity. The syndrome ... of the global marketplace, which for the purposes of ...
(Date:5/27/2015)... Protein purification involves the process of isolating ... physical properties. The objective of a protein purification process ... with fewest contaminants. The global protein purification and isolation ... around 5% to 6% during the forecast period. This ... pharmaceutical and biotechnological fields, growing need to identify new ...
(Date:5/27/2015)... May 27, 2015 ... has announced the addition of the  "2015 ... Market"  report to their offering. ... issues pertaining to the US NAT laboratory ... demographic, social and technological trends with significant ...
Breaking Medicine Technology:OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 3OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 4Protein Purification & Isolation Market by Technology by Product by Application & End User - Global Forecast to 2020 2Protein Purification & Isolation Market by Technology by Product by Application & End User - Global Forecast to 2020 3United States Nucleic Acid Testing Market Strategies 2015-2020 2
... February 23 BN,ImmunoTherapeutics, Inc. today provided updated ... vaccine, MVA-BN(R)-HER2, in development as,therapy of metastatic breast ... its primary endpoint with regards to safety and ... immune response was,detected in approximately 70% of evaluated ...
... An international team of,researchers has evaluated ... the knee, and the results have been ... journal "Osteoarthritis and Cartilage".,The researchers followed 376 ... treatments. After six months as well as ...
Cached Medicine Technology:BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine 2BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine 3New Treatment Against Osteoarthritis: Orthokine Therapy Highly Effective Against Knee Arthritis After Two Years 2
(Date:5/27/2015)... 27, 2015 While hair transplantation has ... a new pilot study conducted by a physician member ... has found hair follicle grafting can help treat patients ... partially funded by ISHRS, which offers research grants for ... restoration. , In the past decade, numerous scientific ...
(Date:5/27/2015)... 2015 NOVAtime Technology, Inc. ( ... solutions for enterprise organizations, announced today that SanMar ... automate its time, attendance and point tracking processes ... the United States. , Family-owned since 1971, ... 21 retail, private label, and mill brands. SanMar ...
(Date:5/27/2015)... ABILENE, Texas (PRWEB) May 27, 2015 ... addition of three FDA-approved dermal filler treatments in Abilene, ... designed to reduce the appearance of glabellar lines, better ... lines. Belotero Balance® is designed to treat smoker’s ... mouth to the chin, while Radiesse® improves the appearance ...
(Date:5/27/2015)... On June 5, Plan B [the ... with LifeSource to host Donate Your Break, a public ... a LifeSource donor coach outside of 116 W. Illinois ... Demand for whole blood units is highest for LifeSource, ... months. LifeSource requires approximately 1,000 donations per day to ...
(Date:5/27/2015)... San Francisco, CA (PRWEB) May 27, 2015 ... into a total communication environment where the message is not ... face, a toy, drawing, or virtually any motivating image. This ... iPad has to offer. , Now, using InnerVoice ... same messages can be sent to a learner remotely for ...
Breaking Medicine News(10 mins):Health News:New Research Finds Hair Grafting a Promising Therapy for Chronic Leg Ulcers - International Society of Hair Restoration Surgery Awards Research Grant 2Health News:New Research Finds Hair Grafting a Promising Therapy for Chronic Leg Ulcers - International Society of Hair Restoration Surgery Awards Research Grant 3Health News:SanMar Corporation Successfully Implemented NOVAtime Workforce Management Solution across 9 locations 2Health News:SanMar Corporation Successfully Implemented NOVAtime Workforce Management Solution across 9 locations 3Health News:The MedSpa at Hendrick Introduces Xeomin®, Belotero Balance® and Radiesse® Injectables 2Health News:Donate Your Break and Save Lives at the River North Blood Drive 2Health News:Newly Released: InnerVoice Sender App Ups the Ante in Communication Technology for Autism with Remote Prompting 2Health News:Newly Released: InnerVoice Sender App Ups the Ante in Communication Technology for Autism with Remote Prompting 3Health News:Newly Released: InnerVoice Sender App Ups the Ante in Communication Technology for Autism with Remote Prompting 4
... BEND, Ore., Oct. 20 Bend Research Inc. ... expertise and,technologies to outside firms in the pharmaceutical ... 23-year collaboration with Pfizer but,will also be free ... jointly by the two firms., These technologies ...
... Study finds increased risk of death, heart attacks , , MONDAY, ... doubts about using beta blockers to reduce the risks of ... before non-cardiac surgery was 10 times higher in the 30 ... drugs (2.52 percent vs. 0.25 percent), according to a report ...
... Oct. 20 /PRNewswire/ - Ocean Nutrition Canada Limited ... oil to the food and,dietary supplement industries is ... investment secures ONC,s position as the largest,fish oil ... their world class molecular distillation plant in,Mulgrave, Nova ...
... Insulet Corporation,(Nasdaq: PODD ), the leader in patch ... the appointment of Sally W.,Crawford to its board of ... chief operating officer of Healthsource Inc., a managed care,organization. ... venture,capital firm in life sciences, on Insulet,s board of ...
... treatment in these patients , , MONDAY, Oct. 20 (HealthDay ... risk of fractures, particularly of potentially crippling breaks in ... study of more than 16,000 heart disease patients treated ... a more than fourfold higher incidence of fractures among ...
... Offer ,The Prevention Plan(TM), Health Management Program to ... ... U.S. Preventive Medicine(R), the leader,in disease prevention, today announced that the ... golf tournaments to amateur golfers in the Metro Atlanta area,will offer ...
Cached Medicine News:Health News:Bend Research Offers Broad Access to Drug-Delivery Solutions 2Health News:Questions Continue About Using Beta Blockers Before Surgery 2Health News:Questions Continue About Using Beta Blockers Before Surgery 3Health News:Ocean Nutrition Canada Limited Secures Their Position as the Largest Omega-3 EPA/DHA Ingredient Supplier in the World 2Health News:Sally W. Crawford Joins Insulet's Board of Directors 2Health News:Sally W. Crawford Joins Insulet's Board of Directors 3Health News:Sally W. Crawford Joins Insulet's Board of Directors 4Health News:Heart Failure Raises Risk of Fractures 2Health News:Heart Failure Raises Risk of Fractures 3Health News:U.S. Preventive Medicine(R) Tees Up with Amateur Golf Association 2
For the quantitative in vitro determination of Magnesium in serum, plasma and urine...
For the quantitative in vitro determination of Anti-Streptolysin-O (ASO) in serum...
For the quantitative in vitro determination of IgE in Human Serum or Plasma....
Latex agglutination slide test for the qualitative and semi-quantitative in vitro determination of CRP in serum....
Medicine Products: